• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

The Investment Angle of Covid-19

Stocks of companies that have Covid-19 vaccine candidates have boomed while those in the treatment space have not.
By JIM COLLINS
Oct 02, 2020 | 11:13 AM EDT
Stocks quotes in this article: MRNA, ARCT, CVAC, GILD, ABC

As the markets wheeze in Friday's trading on news that President Trump and the First Lady have tested positive for Covid-19, it brings up a question: why are the global stock markets so focused on finding a cure for Covid-19 -- in the form of a vaccine -- instead of a treatment? People are going to contract SARS-CoV-2, and they continue to do so rapidly. As of this writing, planet Earth has crossed the 34 million cases threshold. With India rapidly gaining on the U.S. and likely to exceed our case total by the end of next week, shouldn't we, as a society be more focused on the one million folks that have died from this super-flu than the >95% plus that have had it (with or without symptoms) and processed it as we, as a planet, move towards herd immunity?

I will leave that question hanging, but I am a stock guy, not a science guy, so let's look at the investment angle here. Stocks of companies that have Covid-19 vaccine candidates have boomed (Moderna (MRNA) is now worth $29 billion despite having almost zero revenues) while those in the treatment space have not. The frequency and magnitude of insider selling at Moderna is something that I have rarely seen in my 28 years as a stock analyst and, frankly, it's gross. Why would anyone want to be on the other side of that and buy what Moderna insiders are selling?

It's simple. Because mRNA technology offers the prospect of teaching the body how to fight off infections itself, and thus turn the human body into a drug-producing machine. It's a powerful concept, but is really only in infant stages. As I have mentioned in prior RM columns, I own Arcturus Therapeutics (ARCT) (which has a Covid-19 vaccine candidate currently in stage 1-2 testing at Duke-NUS hospital in Singapore) but as a professional portfolio manager I can't afford for my clients' portfolios to be composed solely of longshots.

So, I will pass on Moderna and the even-less-robust-from-a-corporate-standpoint names like CureVac (CVAC) and look for treatment stocks. Here in the U.S. all roads (and Google searches) lead to Gilead (GILD) as a Covid-19 treatment play via its antiviral drug, remdesivir. If Mr. Market is never wrong, then he is telling us that either a) remdesivir is not an appropriate treatment or b) these vaccines (using mRNA or traditional technologies) will be approved in short order and there won't be a need for treatments like remdesivir.

That's a mutli-faceted bet and I like to invest in cases where I can reduce the outcome matrix to one variable. In any case, GILD has been a flat-out dog in the past three months. It's down slightly today, down more than 25% since the all-time high of $86 per share reached at the beginning of May, and is trading almost exactly at its level of one year ago when so many other names with an "Rx" attached to them have gone completely bananas.

This is where an investor has to be VERY careful, and I have to insert the disclaimer "I am not a scientist." Gilead announced yesterday that it would take over distribution of remdesivir (branded as Veklury) as its distribution agreement with the U.S government has expired. AmerisourceBergen (ABC) will aid Gilead in distributing Veklury directly to hospitals.

As stated in the documentation included at remdesir.com.

  • VEKLURY is an investigational drug that has not been approved by the FDA for any use. It is not yet known if VEKLURY is safe and effective for the treatment of Covid-19.
  • The distribution of VEKLURY has been authorized only for the treatment of hospitalized patients with Covid-19. This use is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use, unless the authorization is terminated or revoked sooner.
  • The FDA issued this EUA, requested by Gilead Sciences and based on their submitted data.

Oh, man. Why didn't I pay more attention in science classes as a kid? Remember, though, Veklury is in Phase 3 trials in the U.S. It has NOT been approved and is only being prescribed currently under the aegis of the FDA's Emergency Use Authorization.

The market has shown us that Gilead stock was waaaay ahead of itself in May, and I believe history is going to repeat with Moderna. Don't be a guinea pig with healthcare stocks. Stick to companies with established -- approved -- drugs and the cash flows that accrue from them and you will sleep better at night.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jim Collins' firm owned ARCT.

TAGS: Drug Approvals | Investing | Markets | Stocks | Trading | Pharmaceuticals | Coronavirus

More from Investing

Buying Will Get You Nowhere If You Don't Know How to Sell

James "Rev Shark" DePorre
May 28, 2022 10:00 AM EDT

Let's explore the tremendous power of the sell button -- and why it's so emotionally charged.

Move Over Target and Walmart, Costco Gets the Gold Star

Stephen Guilfoyle
May 28, 2022 7:30 AM EDT

I had a bit of money -- and ego -- riding on Costco coming into earnings. It didn't disappoint.

A Rally Driven by Fear (of Missing Out)

James "Rev Shark" DePorre
May 27, 2022 4:28 PM EDT

What's next after this seesaw week? One thing is for sure: More volatility.

Let's Take Nikola for a Spin. And Then Return It

Mark Sebastian
May 27, 2022 2:56 PM EDT

I wouldn't want to own NKLA, but I could see riding it for a few days.

In Awe of Marvell's Rally? Check the Charts, Not Your Emotions

Bruce Kamich
May 27, 2022 2:03 PM EDT

Here's why you should stay nimble as you approach MRVL after its post-earnings upswing.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The tremendous power of the sell button.
  • 02:46 PM EDT STEPHEN GUILFOYLE

    We're Shedding Some of This Holding on Strength

    Check out the Stocks Under $10 portfolio here!
  • 11:33 AM EDT PETER TCHIR

    Thoughts Ahead of the Fed Minutes

    Recent economic and earnings issues are convincing...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login